Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT: JNJ-77242113 in Moderate-to-Severe Plaque Psoriasis
NCT05357755Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of icotrokinra in plaque psoriasis, sponsored by Janssen Pharmaceutical. Started Jun 2022; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05357755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357755.